Wednesday, October 21, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

News articleYahoo Finance· July 29, 2026

UBS Starts $3 Billion Buyback Plan as Investment Bank Surges

View original at finance.yahoo.com

UBS Starts $3 Billion Buyback Plan as Investment Bank Surges (Bloomberg) -- UBS Group AG announced a new $3 billion share buyback program, aided by a quarter in which wealth management assets beat estimates and trading revenue surged…

Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

UBS reported a strong set of results, not unexpected post peer results.
60% confidence
The top line benefited from supportive markets and operating leverage meant a large part went through to profits.
60% confidence
Client activity remains healthy, though the outlook for the upcoming quarter is cautious given ongoing Middle East conflict and volatile energy prices.
60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date

October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,406 source documents archived

Query this data → isubstrate.com